Global Tuberculosis Drug Market 2017-2021

Global outlook of the tuberculosis (TB) drug market

Technavio's market research analysts predict the global tuberculosis drug market to grow steadily during the forecast period and post a CAGR of more than 3% by 2021. This industry research report identifies the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) strains to be one of the major factors that will have a positive impact on the growth of this market in the coming years. The recent years witnessed an increase in the emergence of drug-resistant TB, especially in the highly populated countries such as India and China. It has been observed by the Centers for Disease Control and Prevention (CDC) that XDR-TB is present across all regions of the world and is most prevalent in countries of the former Soviet Union and Asia. Countries such as the US, India, Japan are also witnessing an increase in the transmission of MDR-TB. This increase in TB infections will subsequently drive the demand for TB drugs in the coming years, in turn, aiding market growth.

This market research and analysis estimates that in terms of geographical regions, the Americas will be the major revenue contributor to the TB drugs market throughout the predicted period. Due to factors such as the reduction or stagnant funding for TB prevention efforts in the US, major states such as California, Florida, New York, and Texas reported an increase in the incidence rate of tuberculosis during 2015. This growing incidence rate of TB in the region will be the primary factor for the growth of the market in the Americas.

Competitive landscape and key vendors

The market is oligopoly in nature since there are a very few players who manufacture drugs for tuberculosis and is dominated by the major players such as Sanofi, Otsuka Novel Products, Pfizer, Sandoz, and Lupin. TB drug manufacturers increasingly focus on amplifying their sales volume through both the direct and distributors channels. To increase their revenue shares major vendors are concentrating on launching new products and few vendors are also focusing on organizing anti-TB campaigns to detect, combat, and create awareness about the disease.

The leading vendors in the market are -

• Lupin
• Otsuka Novel Products
• Pfizer
• Sandoz
• Sanofi

The other prominent vendors in the market are AstraZeneca, Archivel Farma, bioMérieux, Cepheid, EIKEN CHEMICAL, and Epistem.

Segmentation by disease type and analysis of the TB drug market

• Active TB
• Latent TB

Since latent tuberculosis infection (LTI) has the potential to develop into active infection if unidentified, countries in the developed regions such as North America and Europe and countries such as Japan, Australia, and New Zealand are increasingly focusing on performing tuberculosis skin tests (TST) for the early detection, diagnosis, and prevention of the disease.

Segmentation by drug class and analysis of the TB drug market

• First-line anti-TB drugs
• Second-line anti-TB drugs

The first-line anti-TB drugs segment accounted for the maximum revenue and dominated the TB drug market during 2016. Individuals with drug-susceptible TB have the need to take the first-line anti-TB drugs daily for a minimum of six months. According to this market research and analysis, this segment will continue to dominate the market throughout the predicted period as well.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global tuberculosis (TB) drug market?
• What are the key market trends impacting the growth of the global tuberculosis (TB) drug market?
• What are the challenges to market growth?
• Who are the key vendors in the global tuberculosis (TB) drug market?
• What are the market opportunities and threats faced by the vendors in the global tuberculosis (TB) drug market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global tuberculosis (TB) drug market?

Technavio also offers customization on reports based on specific client requirement.

Related reports

• Global Atopic Dermatitis Drugs Market 2017-2021
• Global Multiple Myeloma Drugs Market 2017-2021
• Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

Industries such as molecular biology, genetics, biotechnology, and cell biology are in constant need for life science research tools inducing pharmaceutical companies to compete to gain a considerable revenue share of the market. By identifying the trends in consumer behavior, competitors, growth potential, and challenges, market research experts at the global market research firm Technavio provide an exhaustive collection of industry research reports on the various aspects of the cardiovascular and metabolic disorders sector, which is an integral part of the healthcare and life sciences industry. The market research reports from Technavio also provide detailed information on several vendors, including Allergan, Merck, Allergy Therapeutics, Novartis, GSK, Shire, and Sandoz who have established a significant presence in the industry.

To understand the industry's growth prospects, the market research experts at Technavio have followed an approach consisting of primary and secondary research methodologies and also have considered factors like the market size and the demand for various products across different geographical regions. With comprehensive information on various parameters such as the changing preferences of consumers, products offered by competitors, and the optimal usage of analytical tools, our upcoming market research report on tuberculosis drugs for the forecast period of 2017 to 2021 will help clients understand the constantly changing landscape of the healthcare sector.

This upcoming report on tuberculosis drugs also considers the growth of the similar markets such as the next-generation biologics and metabolic disorders therapeutics market, which are expected to grow at a CAGR of around 14% and 5%, respectively by 2020. According to our experts, the increasing demand for antibody drug conjugates (ADCs) is one of the significant factors driving the demand for tuberculosis drugs. Along with syndicated reports, Technavio also offers to provide customized reports based on the requirements of the clients to help businesses optimize their market position.

The upcoming industry research report for antifungal drugs also identifies the key drivers, emerging trends, as well as the challenges currently experienced by the cardiovascular and metabolic diseases sector. It also presents insights into the changing competitive landscape to give you a realistic picture of the future direction of the healthcare and life sciences industry.